Trastuzumab emtansine (T-DM1), an antibody–drug conjugate (ADC) of trastuzumab with the microtubule inhibitor emtansine, has been developed and is being investigated as part of neoadjuvant therapy for HER2 + breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.